Display options
Cite
Helm A, Ebner DK, Tinganelli W, et al. Combining Heavy-Ion Therapy with Immunotherapy: An Update on Recent Developments. Int J Part Ther. 2018;5(1):84-93doi: 10.14338/IJPT-18-00024.1.
Helm, A., Ebner, D. K., Tinganelli, W., Simoniello, P., Bisio, A., Marchesano, V., Durante, M., Yamada, S., & Shimokawa, T. (2018). Combining Heavy-Ion Therapy with Immunotherapy: An Update on Recent Developments. International journal of particle therapy, 5(1), 84-93. https://doi.org/10.14338/IJPT-18-00024.1
Helm, Alexander, et al. "Combining Heavy-Ion Therapy with Immunotherapy: An Update on Recent Developments." International journal of particle therapy vol. 5,1 (2018): 84-93. doi: https://doi.org/10.14338/IJPT-18-00024.1
Helm A, Ebner DK, Tinganelli W, Simoniello P, Bisio A, Marchesano V, Durante M, Yamada S, Shimokawa T. Combining Heavy-Ion Therapy with Immunotherapy: An Update on Recent Developments. Int J Part Ther. 2018;5(1):84-93. doi: 10.14338/IJPT-18-00024.1. Epub 2018 Sep 21. PMID: 31773022; PMCID: PMC6871592.
Copy Download .nbib Format: NLM
Share it on

Int J Part Ther. 2018;5(1):84-93. doi: 10.14338/IJPT-18-00024.1. Epub 2018 Sep 21.

Combining Heavy-Ion Therapy with Immunotherapy: An Update on Recent Developments.

International journal of particle therapy

Alexander Helm, Daniel K Ebner, Walter Tinganelli, Palma Simoniello, Alessandra Bisio, Valentina Marchesano, Marco Durante, Shigeru Yamada, Takashi Shimokawa

Affiliations

  1. Trento Institute for Fundamental Physics and Applications-National Institute for Nuclear Physics, Trento, Italy.
  2. Brown University Alpert Medical School, Providence, RI, USA.
  3. Hospital of the National Institute of Radiological Sciences, National Institutes of Quantum and Radiological Science and Technology, Chiba, Japan.
  4. Department of Science and Technology, Parthenope University of Naples, Naples, Italy.
  5. Center for Integrative Biology (CIBIO), University of Trento, Trento, Italy.
  6. National Institute of Radiological Sciences, National Institutes of Quantum and Radiological Science and Technology, Chiba, Japan.

PMID: 31773022 PMCID: PMC6871592 DOI: 10.14338/IJPT-18-00024.1

Abstract

Clinical trials and case reports of cancer therapies combining radiation therapy with immunotherapy have at times demonstrated total reduction or elimination of metastatic disease. While virtually all trials focus on the use of immunotherapy combined with conventional photon irradiation, the dose-distributive benefits of particles, in particular the distinct biological effects of heavy ions, have unknown potential vis-a-vis systemic disease response. Here, we review recent developments and evidence with a focus on the potential for heavy-ion combination therapy.

©Copyright 2018 International Journal of Particle Therapy.

Keywords: abscopal effect; combination immunotherapy-radiotherapy; heavy-ion radiotherapy; radiation-induced immunogenic cell death

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to disclose.

References

  1. Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):793-8 - PubMed
  2. Ann Transl Med. 2016 Mar;4(6):118 - PubMed
  3. Br J Radiol. 2014 Mar;87(1035):20130626 - PubMed
  4. Front Oncol. 2018 May 29;8:192 - PubMed
  5. Oncoimmunology. 2014 May 14;3:e28780 - PubMed
  6. Sci Transl Med. 2016 Aug 17;8(352):352ra110 - PubMed
  7. Int J Radiat Biol. 2005 Nov;81(11):841-54 - PubMed
  8. Oncoimmunology. 2015 May 27;4(10):e1042198 - PubMed
  9. Physiol Res. 2014;63(4):409-20 - PubMed
  10. Cell Death Dis. 2016 Dec 8;7(12):e2518 - PubMed
  11. Radiat Res. 2001 Jan;155(1 Pt 1):32-42 - PubMed
  12. J Exp Med. 2011 Sep 26;208(10):1989-2003 - PubMed
  13. Radiat Res. 2011 Oct;176(4):434-46 - PubMed
  14. JAAD Case Rep. 2016 Dec 03;2(6):439-441 - PubMed
  15. BMC Cancer. 2013 Mar 25;13:151 - PubMed
  16. Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14188-93 - PubMed
  17. Oncoimmunology. 2014 Apr 16;3:e28473 - PubMed
  18. Clin Cancer Res. 2018 Jan 15;24(2):259-265 - PubMed
  19. Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):591-7 - PubMed
  20. J Hematol Oncol. 2018 Mar 15;11(1):39 - PubMed
  21. Front Oncol. 2017 Apr 07;7:66 - PubMed
  22. Immunity. 2014 Nov 20;41(5):843-52 - PubMed
  23. Mutat Res. 2007 Aug 15;632(1-2):58-68 - PubMed
  24. Nat Rev Cancer. 2018 May;18(5):313-322 - PubMed
  25. Front Oncol. 2016 Jun 10;6:130 - PubMed
  26. Adv Radiat Oncol. 2017 Jun 07;2(3):333-338 - PubMed
  27. Mol Cancer Res. 2017 Nov;15(11):1579-1586 - PubMed
  28. Nat Rev Cancer. 2012 Oct;12(10):663-70 - PubMed
  29. Mutat Res. 2017 Jan - Mar;771:85-98 - PubMed
  30. Oncoimmunology. 2014 Apr 25;3:e28518 - PubMed
  31. Trends Mol Med. 2013 Sep;19(9):565-82 - PubMed
  32. J Exp Med. 2011 Sep 26;208(10):2005-16 - PubMed
  33. Nat Rev Clin Oncol. 2017 Aug;14(8):483-495 - PubMed
  34. Cancer. 2010 Aug 1;116(15):3740-8 - PubMed
  35. Mutagenesis. 1996 Jul;11(4):307-13 - PubMed
  36. Acta Oncol. 2001;40(6):682-5 - PubMed
  37. Nat Rev Immunol. 2017 Feb;17(2):97-111 - PubMed
  38. PLoS One. 2011;6(11):e28217 - PubMed
  39. Radiat Environ Biophys. 2015 Aug;54(3):297-304 - PubMed
  40. Int J Radiat Biol. 2000 Apr;76(4):539-47 - PubMed
  41. Radiat Res. 1996 Feb;145(2):188-99 - PubMed
  42. Nature. 2017 Aug 24;548(7668):461-465 - PubMed
  43. Oncoimmunology. 2017 Jun 16;6(9):e1339857 - PubMed
  44. Nature. 2017 Aug 24;548(7668):466-470 - PubMed
  45. Cancer Res. 2005 Jan 1;65(1):113-20 - PubMed
  46. Int J Radiat Biol. 2011 Jan;87(1):71-80 - PubMed
  47. Neoplasia. 2014 Apr;16(4):319-28 - PubMed
  48. Lancet Oncol. 2015 Feb;16(2):e93-e100 - PubMed
  49. Int J Mol Sci. 2017 Aug 03;18(8):null - PubMed
  50. Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):934-936 - PubMed
  51. J Natl Cancer Inst. 2013 Feb 20;105(4):256-65 - PubMed
  52. Nat Commun. 2017 Jun 09;8:15618 - PubMed
  53. Biochem Pharmacol. 2018 Jul;153:46-50 - PubMed
  54. Front Oncol. 2016 Jan 20;6:5 - PubMed
  55. Chronobiol Int. 2017;34(4):492-503 - PubMed
  56. J Radiat Res. 2017 Jul 1;58(4):446-455 - PubMed
  57. In Vivo. 2011 Jan-Feb;25(1):1-9 - PubMed
  58. Sci Rep. 2015 Jul 21;5:12362 - PubMed
  59. Cell Death Differ. 2014 Jan;21(1):92-9 - PubMed
  60. N Engl J Med. 2012 Mar 8;366(10):925-31 - PubMed
  61. Radiat Environ Biophys. 2015 Aug;54(3):327-34 - PubMed
  62. Int J Mol Sci. 2017 Nov 06;18(11):null - PubMed
  63. Cancer Cell. 2015 Dec 14;28(6):690-714 - PubMed
  64. Cancer Sci. 2009 Feb;100(2):303-9 - PubMed
  65. Curr Breast Cancer Rep. 2017;9(1):45-51 - PubMed
  66. Front Immunol. 2017 Feb 06;8:99 - PubMed
  67. Nature. 2012 Jan 18;482(7383):53-8 - PubMed
  68. Mol Cell. 2013 Jul 25;51(2):226-35 - PubMed
  69. Physiol Rev. 2010 Oct;90(4):1383-435 - PubMed
  70. Nature. 2008 Oct 2;455(7213):674-8 - PubMed
  71. Radiat Res. 2014 Oct;182(4):363-7 - PubMed
  72. Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):120-30 - PubMed
  73. Acta Oncol. 2014 Jan;53(1):25-32 - PubMed
  74. Nat Commun. 2015 Jan 21;6:5990 - PubMed
  75. Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1524-31 - PubMed
  76. Cell Death Differ. 2007 Oct;14(10):1848-50 - PubMed
  77. Adv Drug Deliv Rev. 2017 Jan 15;109:63-73 - PubMed
  78. J Exp Med. 2006 May 15;203(5):1259-71 - PubMed
  79. Phys Med Biol. 2017 Sep 20;62(19):7798-7813 - PubMed
  80. Sci Rep. 2015 Sep 04;5:13815 - PubMed
  81. Oncotarget. 2014 Jan 30;5(2):403-16 - PubMed
  82. Cancer Immunol Immunother. 2014 Oct;63(10):1009-21 - PubMed
  83. Cancer Sci. 2014 Jul;105(7):770-8 - PubMed

Publication Types